Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
AssigneeSpectrum Pharmaceuticals, Inc.
InventorsJohn A. Barrett, Sribalaji Lakshmikanthan
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer at a fixed dose regardless of the patient's weight.
Claims20
A method of prophylactically treating a patient in need thereof at risk of developing a compromised white blood cell production, the method comprising identifying a patient at risk of developing chemotherapy induced condition after at least once cycle of chemotherapy regimen, administering to the patient a therapeutically effective amount of EFLAPEGRASTIM at a fixed dose once per chemotherapy cycle.
Dependencies are inferred from the claim text.